Hypertension: key endpoint results by drug

The key endpoints of Hypertension trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Hypertension page.

Seated SBP, change

Seated SBP, change in Hypertension: 4 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Aprocitentan-15.3-11.5−3.812.5 mg · wk 4 · n 243NCT03541174 Phase 3, primary
Baxdrostat-15.7-5.8−9.92 mg · wk 12 · n 266NCT06034743 Phase 3, primary
Sacubitril/valsartan-20.2-13.2 (Olmesartan)—400 mg · wk 8 · n 385NCT01599104 Phase 3, primary
Zilebesiran-11.1-0.6−10.5300 mg Q6M · wk 24 · n 68NCT04936035 Phase 2, secondary

Drugs checked with no result here: 10 not posted, 5 trial running, 6 not reported.

24-hour ambulatory SBP, change

24-hour ambulatory SBP, change in Hypertension: 3 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Baxdrostat-16.6-2.6−142 mg · wk 12 · n 89NCT06168409 Phase 3, primary
Sacubitril/valsartan-4.3-1.0 (Olmesartan)—200 mg · wk 8 · n 167NCT01876368 Phase 3, primary
Zilebesiran-8.96.8−15.7600 mg Q6M · wk 12 · n 65NCT04936035 Phase 2, primary

Drugs checked with no result here: 10 not posted, 6 trial running, 6 not reported.

Seated DBP, change

Seated DBP, change in Hypertension: 4 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Aprocitentan-10.4-6.5−3.912.5 mg · wk 4 · n 243NCT03541174 Phase 3, secondary
Baxdrostat-6.9-3−3.92 mg · wk 12 · n 266NCT06034743 Phase 3, secondary
Sacubitril/valsartan-8.8-6.9 (Olmesartan)—400 mg · wk 8 · n 469NCT01785472 Phase 3, secondary
Zilebesiran-6.8-1.2−5.6300 mg Q6M · wk 24 · n 68NCT04936035 Phase 2, secondary

Drugs checked with no result here: 10 not posted, 5 trial running, 6 not reported.

  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 25 approved or late-stage drugs with a featured trial in Hypertension were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.